Wall Street analysts currently provide no formal consensus revenue or EPS estimates for Amesite's Q3 2026 report, as the micro-cap company remains thinly covered; the stock is currently trading around $0.57, well below the average analyst price target of $7.00.
Investors are primarily focused on the commercial scaling and adoption rates of the company’s flagship NurseMagic AI platform within the healthcare sector.
Recent milestones include a pivot to an enterprise pricing model designed for 85% gross margins and the expansion of its patient census to over 2,700 users. However, market participants remain cautious regarding the company's liquidity and going-concern risks as it prioritizes aggressive software development.